Tarsus to Join Fireside Chat at 2024 Bank of America Healthcare Conference

IRVINE, Calif., May 09, 2024 — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company dedicated to addressing unmet medical needs by leveraging advanced science and technology, has announced that Bobak Azamian, M.D., Ph.D., the company's Chief Executive Officer and Chairman, will be participating in an in-person fireside chat at the 2024 Bank of America Healthcare Conference. This event will be held in Las Vegas, NV, on Wednesday, May 15, at 1:55 p.m. PT / 4:55 p.m. ET.

The presentation will be available via live webcast, and further details can be accessed on the events section of Tarsus' website. Additionally, a replay of the presentation will be accessible on the website within 48 hours and will be archived for a limited period.

Tarsus Pharmaceuticals, Inc. is committed to transforming patient care by applying proven scientific principles and innovative technologies, initially focusing on eye care. The company is actively advancing its product pipeline to address several diseases with significant unmet needs across various therapeutic categories, which include eye care, dermatology, and infectious disease prevention.

One of Tarsus' notable achievements is the FDA approval of XDEMVY® (lotilaner ophthalmic solution) 0.25%, which is used for treating Demodex blepharitis. Furthermore, Tarsus is developing several investigational therapies, which are currently in Phase 2 trials. These include TP-03 for the treatment of Meibomian Gland Disease, TP-04 for treating rosacea, and TP-05, an oral tablet aimed at preventing Lyme disease.

By focusing on these key areas, Tarsus Pharmaceuticals is positioning itself as a leader in the healthcare sector, particularly in addressing conditions that have high unmet medical needs. The company’s strategy involves both innovation in treatment options and a commitment to improving patient outcomes through the application of cutting-edge science.